QIAGEN and Oxford Immunotec Settle Patent Infringement Lawsuit

GERMANTOWN, Maryland and HILDEN, Germany, December 15, 2017 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN, Frankfurt Stock Exchange: QIA) and Oxford Immunotec Ltd. (NASDAQ: OXFD) announced today that they have reached a settlement in the lawsuit in the U.S. District Court for the District of Massachusetts in Boston (15-cv-13124-NMG) alleging patent infringement in relation to QIAGEN's QuantiFERON®-TB Gold and QuantiFERON®-TB Gold Plus products.

Under terms of the agreement, all pending claims between Oxford and QIAGEN and the co-defendants have been resolved. As part of the settlement, Oxford has granted QIAGEN a royalty-free, non-exclusive license that extends to all current and future customers of QuantiFERON-TB Gold and QuantiFERON-TB Gold Plus in exchange for a one-time, lump-sum payment of $27.5 million. The settlement includes general releases of all parties with no admissions of wrongdoing.

This agreement does not affect QIAGEN's adjusted EPS outlook for the fourth quarter and full-year 2017 since these one-time costs are excluded from adjusted results.  

Click here for the full press release

https://corporate.qiagen.com/newsroom/press-releases/2017/20171215_QGEN_OXFD?sc_lang=en  

Contacts: 

QIAGEN 

Investor Relations                     
John Gilardi        
+49-2103-29-11711  
e-mail: [email protected]                          

Public Relations
Dr. Thomas Theuringer
+49-2103-29-11826
e-mail: [email protected]

SOURCE QIAGEN